Current Hematologic Malignancy Reports

, Volume 5, Issue 1, pp 15–21 | Cite as

New Drugs for the Treatment of Myelofibrosis



Managing patients with myelofibrosis (MF)—either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia—presents many challenges to the hematologist. Cure is potentially achievable through allogeneic stem cell transplantation, but this therapy is either inappropriate or not feasible for most patients. MF patients suffer from a range of debilitating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and transformation to a treatment-refractory blast phase). Currently available therapies are palliative but can be of significant value to some MF patients for anemia, splenomegaly, or sometimes both manifestations. New medical therapies for MF revolve around three main themes: immunomodulation (to assist anemia), hypomethylation strategies, and (the most robust pipeline) the use of targeted JAK2 inhibitors. These latter agents have shown the ability to improve MF-associated splenomegaly and MF-associated symptoms but do not improve (and may exacerbate) anemia or thrombocytopenia. Future targeted agents, and perhaps combinations of agents that currently show complementary benefits, are anticipated to further enhance the efficacy of medical therapy for MF.


Myelofibrosis Myeloproliferative disorder JAK2 



No potential conflict of interest relevant to this article was reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Tefferi A, Thiele J, Orazi A, et al.: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092–1097.CrossRefPubMedGoogle Scholar
  2. 2.
    Mesa RA, Niblack J, Wadleigh M, et al.: The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 2007, 109:68–76.CrossRefPubMedGoogle Scholar
  3. 3.
    Mesa RA, Li CY, Ketterling RP, et al.: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005, 105:973–977.CrossRefPubMedGoogle Scholar
  4. 4.
    • Cervantes F, Dupriez B, Pereira A, et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2985–2901. This key reference for the prognosis of patients with primary myelofibrosis is the most definitive prognostic paper to date, drawing on experience with over 1000 patients.CrossRefGoogle Scholar
  5. 5.
    Reilly JT: Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997, 11:233–242.CrossRefPubMedGoogle Scholar
  6. 6.
    Koch CA, Li CY, Mesa RA, Tefferi A: Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003, 78:1223–1233.CrossRefPubMedGoogle Scholar
  7. 7.
    Anger BR, Seifried E, Scheppach J, Heimpel H: Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 1989, 67:818–825.CrossRefPubMedGoogle Scholar
  8. 8.
    Deeg HJ, Gooley TA, Flowers ME, et al.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912–3918.CrossRefPubMedGoogle Scholar
  9. 9.
    Rondelli D, Barosi G, Bacigalupo A, et al.: Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 1–5:4115–4119.CrossRefGoogle Scholar
  10. 10.
    Kroger N, Holler E, Kobbe G, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2009 Oct 7 (Epub ahead of print).Google Scholar
  11. 11.
    Rodriguez JN, Martino ML, Dieguez JC, Prados D: rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998, 83:616–621.PubMedGoogle Scholar
  12. 12.
    Besa EC, Nowell PC, Geller NL, Gardner FH: Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982, 49:308–313.CrossRefPubMedGoogle Scholar
  13. 13.
    Cervantes F, Hernandez-Boluda JC, Alvarez A, et al.: Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000, 85:595–599.PubMedGoogle Scholar
  14. 14.
    Levy V, Bourgarit A, Delmer A, et al.: Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996, 53:239–241.CrossRefPubMedGoogle Scholar
  15. 15.
    Lofvenberg E, Wahlin A: Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988, 41:375–381.PubMedCrossRefGoogle Scholar
  16. 16.
    Petti MC, Latagliata R, Spadea T, et al.: Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 116:576–581.CrossRefPubMedGoogle Scholar
  17. 17.
    Faoro LN, Tefferi A, Mesa RA: Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005, 74:117–120.CrossRefPubMedGoogle Scholar
  18. 18.
    Tefferi A, Elliott MA: Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia [letter]. Blood 2000, 96:4007.PubMedGoogle Scholar
  19. 19.
    Canepa L, Ballerini F, Varaldo R, et al.: Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001, 115:313–315.CrossRefPubMedGoogle Scholar
  20. 20.
    Barosi G, Grossi A, Comotti B, et al.: Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 114:78–83.CrossRefPubMedGoogle Scholar
  21. 21.
    Merup M, Kutti J, Birgergard G, et al.: Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002, 19:79–86.CrossRefPubMedGoogle Scholar
  22. 22.
    Elliott MA, Mesa RA, Li CY, et al.: Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 117:288–296.CrossRefPubMedGoogle Scholar
  23. 23.
    Mesa RA, Steensma DP, Pardanani A, et al.: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003, 101:2534–2541.CrossRefPubMedGoogle Scholar
  24. 24.
    Tefferi A, Cortes J, Verstovsek S, et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158–1164.CrossRefPubMedGoogle Scholar
  25. 25.
    List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549–557.CrossRefPubMedGoogle Scholar
  26. 26.
    Tefferi A, Lasho TL, Mesa RA, et al.: Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007, 21:1827–1828.CrossRefPubMedGoogle Scholar
  27. 27.
    Mesa RA, Yao X, Cripe LD, et al.: Lenalidomide and prednisone for primary and post polycythemia vera/essential thrombocythemia myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) phase II trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1753.Google Scholar
  28. 28.
    Quintas-Cardama A, Kantarjian HM, Thomas DA, et al.: Combined therapy with lenalidomide and prednisone renders durable clinical, histopathological, and molecular responses in patients with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 662.Google Scholar
  29. 29.
    Baxter EJ, Scott LM, Campbell PJ, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054–1061.PubMedGoogle Scholar
  30. 30.
    Kralovics R, Passamonti F, Buser AS, et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779–1790.CrossRefPubMedGoogle Scholar
  31. 31.
    James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144–1148.CrossRefPubMedGoogle Scholar
  32. 32.
    Levine RL, Wadleigh M, Cools J: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. Cancer Cell 2005, 7:387–397.CrossRefPubMedGoogle Scholar
  33. 33.
    Pardanani AD, Levine RL, Lasho T, et al.: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472–3476.CrossRefPubMedGoogle Scholar
  34. 34.
    Delhommeau F, Dupont S, Della Valle V, et al.: Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289–2301.CrossRefPubMedGoogle Scholar
  35. 35.
    Pardanani A, Fridley BL, Lasho TL, et al.: Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008, 111:2785–2789.CrossRefPubMedGoogle Scholar
  36. 36.
    Jones AV, Chase A, Silver RT, et al.: JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 41:446–449.CrossRefPubMedGoogle Scholar
  37. 37.
    Olcaydu D, Harutyunyan A, Jager R, et al.: A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41:450–454.CrossRefPubMedGoogle Scholar
  38. 38.
    Muller GW, Chen R, Huang SY, et al.: Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999, 9:1625–1630.CrossRefPubMedGoogle Scholar
  39. 39.
    Schey SA, Fields P, Bartlett JB, et al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004, 22:3269–3276.CrossRefPubMedGoogle Scholar
  40. 40.
    Mesa RA, Verstovsek S, Rivera C, et al.: 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009, 23:180–182.CrossRefPubMedGoogle Scholar
  41. 41.
    Quintás-Cardama A, Tong W, Kantarjian H, et al.: A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008, 22:965–970.CrossRefPubMedGoogle Scholar
  42. 42.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223–232.CrossRefPubMedGoogle Scholar
  43. 43.
    • Verstovsek S, Kantarjian HM, Pardanani AD, et al.: The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ETMF) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1762. INCB018424 is the class-leading JAK2 inhibitor for myelofibrosis, with activity for splenomegaly and MF-associated symptoms.Google Scholar
  44. 44.
    Mesa RA, Verstovsek S, Kantarjian HM, et al.: INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1760.Google Scholar
  45. 45.
    Mesa RA, Schwager S, Radia D, et al.: The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009, 33:1199–1203.CrossRefPubMedGoogle Scholar
  46. 46.
    • Pardanani AD, Gotlib J, Jamieson C, et al.: A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 97. TG101348 is a promising selective JAK2 inhibitor with activity in MF.Google Scholar
  47. 47.
    • Shah NP, Olszynski P, Sokol L, et al.: A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 98. This JAK2 inhibitor ceased development because of neurologic toxicity.Google Scholar
  48. 48.
    Verstovsek S, Tefferi A, Kornblau S, et al.: Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 3543.Google Scholar
  49. 49.
    Rambaldi A, Dellacasa CM, Salmoiraghi S, et al.: A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 100.Google Scholar
  50. 50.
    Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al.: Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004, 127:399–403.CrossRefPubMedGoogle Scholar
  51. 51.
    Manoharan A, Pitney WR: Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 1984, 33:453–459.PubMedGoogle Scholar
  52. 52.
    Najean Y, Rain JD: Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997, 89:2319–2327.PubMedGoogle Scholar
  53. 53.
    Tefferi A, Silverstein MN, Li CY: 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997, 99:352–357.CrossRefPubMedGoogle Scholar
  54. 54.
    Barosi G, Elliot MA, Canepa L, et al.: Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002, 43:2301–2307.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Hematology and OncologyMayo Clinic ArizonaScottsdaleUSA

Personalised recommendations